

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	1	Date of announcement	2023/11/07	Time of announcement	20:41:32
Subject	Results of Phase II clinical trial of OBP-301 presented in the Society for Immunotherapy of Cancer (SITC)				
Date of events	2023/11/07	To which item it meets	Paragraph 53		
Statement	<p>1. Date of occurrence of the event: 2023/11/07</p> <p>2. Company name: Medigen Biotechnology Corp.</p> <p>3. Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4. Reciprocal shareholding ratios: N/A</p> <p>5. Cause of occurrence:</p> <p>Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma (TSE stock code 4588) are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (November 7, 2023), that the results of a Phase II clinical trial of OBP-301 in combination with immune checkpoint inhibitors for the treatment of gastric cancer and gastroesophageal junction cancer (referred to as G/GEJ) were presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) held in San Diego, USA, from November 1 to 5, 2023. As previously announced press release on June 6, 2023, the trial included a total of 16 G/GEJ patients who had received two or more prior treatments with inadequate efficacy.</p> <p>The clinical trial results showed that, following combination therapy of OBP-301 with the anti-PD-1 drug Pembrolizumab, one patient achieved a complete response (CR), two patients had partial responses (PR), and sustained therapeutic effects were observed. Tumor tissue analysis of the CR patient before and after receiving OBP-301 revealed changes in the tumor microenvironment, implying that OBP-301 can eliminate resistance to immune checkpoint inhibitors and other immunotherapies in gastric cancer and gastroesophageal junction cancer, demonstrating its potential for use in subsequent treatments.</p> <p>6. Countermeasures: none</p>				

7. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):

(1) Explanation of the subsequent clinical development progress as an update of the announcement made on June 6, 2023.

(2) New drug development involves lengthy timelines, high costs, and success is not guaranteed. Such factors introduce risks to investments, and investors should exercise caution and careful judgment when considering investments.

(3) Medigen shares the research and development costs of OBP-301 with Oncolys BioPharma, and will also share future commercial benefits.

(3) Link to the announcement by Oncolys BioPharma in Japan:

<https://ssl4.eir-parts.net/doc/4588/tdnet/2354765/00.pdf>